January 15, 2004
The advantages of the hypotensive lipids bimatoprost (Lumigan, Allergan), latanoprost (Xalatan, Pfizer), and travoprost (Travatan, Alcon) over timolol 0.5% (Timoptic, Merck) have been conclusively demonstrated in phase III clinical trials. As a class, these therapies have been shown to reduce IOP and to reduce fluctuations of the diurnal curve significantly. Yet, it is important to understand that despite these commonalities, differences also exist. It is only in understanding these differences, and matching them clinically to the individual profile of the patient, that we can choose the right drug at the right time.